timothy sykes logo
Twist Bioscience (TWST) Stock Rallies On AI Drug Discovery Deals And Target Hikes Thumbnail
G Google News

Twist Bioscience (TWST) Stock Rallies On AI Drug Discovery Deals And Target Hikes

MATT MONACO•UPDATED OCT. 5, 2026, 3:03 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Twist Bioscience Corporation stocks have been trading up by 8.92 percent following upbeat news on synthetic DNA demand growth.

Key Takeaways For TWST Traders

  • Signed a data and services deal to power Eli Lilly’s AI/ML TuneLab antibody discovery platform, integrating Twist Bioscience wet-lab data into Lilly’s models.
  • Leerink twice lifted its TWST price target in September, now at $190, pointing to conservative revenue assumptions and rising pharma adoption of the platform.
  • Guggenheim more than doubled its Twist Bioscience target to $212, reinforcing the AI drug discovery upside ahead of Q3 earnings.
  • UBS initiated TWST at Neutral with a $144 target but still highlighted strong long-term growth prospects for life science tools.
  • Work with Anthropic on AI-designed mini-binder proteins is likely already baked into Twist Bioscience’s 2027 orders outlook, limiting surprise upside from that project.

Candlestick Chart

Live Update At 15:02:39 EDT: On Monday, October 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 8.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TWST is trading like a high-growth, high-expectation story, and the numbers back that up. On the chart, Twist Bioscience just ripped from a recent close of $126.85 on 2026/09/10 to $205.50 on 2026/10/05. That is a powerful uptrend, with only shallow pullbacks along the way. Sessions like 2026/09/24, when TWST jumped 6.9% to $169.38, show strong dip buying and momentum trading interest.

Intraday action on the latest session also matters. Twist Bioscience opened near $189 and steadily pushed toward a $206.22 high before closing at $205.50. The 5‑minute candles show tight ranges and higher lows all afternoon, classic controlled trend behavior rather than wild, random spikes. Traders watching level 2 would see bids stepping up instead of bailing.

More Breaking News

Fundamentally, TWST is still losing money, but revenue is growing. Quarterly sales were about $118.4M with gross margin around 52%, while EBITDA came in at roughly -$27.96M and net loss at -$35.05M. Guidance calls for adjusted EBITDA breakeven by Q4 FY26. With $166.8M in cash and short-term investments, low debt (total debt-to-equity about 0.21), and strong liquidity, Twist Bioscience has runway to chase growth while working toward profitability.

Why Traders Are Watching TWST Right Now

TWST has become a pure-play way to trade the AI drug discovery theme. The Lilly TuneLab agreement is the key catalyst. Twist Bioscience is not trying to be a pharma giant; it is selling the “picks and shovels” for that gold rush. By piping its antibody characterization data and services into Eli Lilly’s AI/ML platform, TWST turns its wet-lab capabilities into a recurring data engine for big pharma models.

The market reaction says traders care. Multiple headlines show Twist Bioscience shares popping after the Lilly TuneLab news, with gains from about 1.5% to more than 4% on the day of the announcement. That kind of clean, news-driven follow‑through is what momentum traders look for: clear catalyst, strong volume, and directional price response.

On the Street side, re‑rating is in full swing. Leerink first took its TWST target from $120 to $160, then again from $160 to $190, each time sticking with an Outperform call. The message is simple: revenue assumptions were conservative, and visibility into pharma adoption of the Twist Bioscience platform is getting better. Guggenheim went even further, more than doubling its target from $107 to $212 while reaffirming Buy ahead of Q3 earnings.

Even the more cautious UBS launch tells a bullish story. UBS started coverage of TWST at Neutral, but with a $144 target that sat well above prior consensus around $87. That effectively dragged the whole target stack higher and signaled that big institutions are recalibrating what Twist Bioscience may be worth as AI drug workflows scale.

Add in the Anthropic mini‑binder protein work—confirmed as real but largely already built into Twist’s 2027 outlook—and TWST looks less like hype and more like an early infrastructure name for AI biology. For active traders, that combination of catalysts, Street upgrades, and thick price momentum is why TWST stays on the screen.

Conclusion

Twist Bioscience is still a loss‑making, high‑multiple name, but the story is shifting. TWST is guiding to adjusted EBITDA breakeven by Q4 FY26, while quarterly revenue tops $118M with expanding margins. That “path to profitability plus AI leverage” is exactly the cocktail that many growth-focused traders hunt for. As long as Twist Bioscience keeps delivering on revenue growth and cost control, the current premium price-to-sales and price-to-book ratios can stay elevated.

At the same time, traders need to remember the risks. Negative EBIT margins near -31.8% and returns on equity around -29% show Twist Bioscience has work to do before it becomes a clean cash machine. Insider activity, like CEO Emily Leproust’s sale of about $923,000 in stock while still holding more than 613,000 shares, is worth tracking but not overreacting to in isolation. Ownership filings and a shifting target landscape tell you this name is heavily watched by institutions.

For short‑term traders, the game plan around TWST centers on catalysts: Lilly TuneLab updates, AI collaboration headlines, earnings, and any revisions to that FY26 breakeven target. Momentum has been strong, but momentum cuts both ways when expectations run hot. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. As Tim Sykes likes to remind his community, “Patterns repeat, but only for traders who study them and cut losses quickly.” With TWST, that means respecting both the powerful AI‑driven uptrend and the volatility that comes with it, using this analysis strictly for educational and research purposes—not as investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”